Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- Baxter ASN Presence, 2018 Posted 10-05-2026
- Fresenius Kidney Care Reports PD Breakthroughs Posted 10-05-2026
- NIH to Consolidate Websites Under Nine Hubs Posted 09-18-2026
- FDA Warns Fresenius About Leaking PD Solution Bags and Particulates Posted 09-18-2026

